Evidence map›Paper›PMID 40741274›Full record

ArticleArchives of medical science : AMS2025

An improved random forest algorithm for tracing the origin of metastatic renal cancer tissues.

HaiDong Li, Tao Xie

Abstract read
In one paragraph

Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

HaiDong LiDepartment of Urology, Chengdu Seventh People's Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu, China.
Tao XieDepartment of Imaging, West China Second Hospital, Sichuan University, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Tracing the histological origin of metastatic renal cancer (MRC) and locating the pathological root cause lead to precise treatment and improved prognosis. Material and methods: A total of 3336 patient cases with clear tissue origins from The Cancer Genome Atlas (TCGA) database were screened as experimental data material and feature selection was performed using the differential expression method; the random forest (RF) algorithm was improved to establish a medical retrospective heterogeneous filtered feature selection random forest weighted (ReliefFk_RFw) model to locate tissue origins. Results: The differential expression analysis method screened 60 signature genes with good differential expression for tracing tissue origins (kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, liver hepatocellular carcinoma, pancreatic adenocarcinoma). Compared with traditional machine learning (support vector machine, decision tree, RF) models, the ReliefFk_RFw algorithm increased the average accuracy from 98.65%, 98.79% and 98.57% to 99.53%, the average precision from 95.58%, 96.40% and 96.54% to 99.36%, and the average sensitivity from 97.03%, 96.61% and 96.76% to 98.89%, mean specificity from 99.50%, 99.39% and 99.35% to 99.90%, and mean F1 score from 96.30%, 96.50% and 96.64% to 99.11%. The highest accuracy in localizing the origin of primary pancreatic cancer was achieved with 100.00% for different models of retrospective metrics. Conclusions: The improved ReliefFk_RFw model is best for comprehensive assessment and can be used to trace the origin of MRC tissue to assist physicians in diagnosis and treatment.

Indexed as

differential expression analysismetastatic renal cancerReliefFk_RFw algorithmTCGA databasetissue origin tracing

Identifiers

PMID40741274
PMCPMC12305792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.